| Diffuse Large B-Cell Lymphoma
Monjuvi vs Zynlonta
Side-by-side clinical, coverage, and cost comparison for diffuse large b-cell lymphoma.Deep comparison between: Monjuvi vs Zynlonta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZynlonta has a higher rate of injection site reactions vs Monjuvi based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zynlonta but not Monjuvi, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Monjuvi
Zynlonta
At A Glance
IV infusion
Every 2 weeks
CD19-directed monoclonal antibody
IV infusion
Every 3 weeks
CD19-directed antibody-drug conjugate
Indications
- Diffuse Large B-Cell Lymphoma
- Diffuse Large B-Cell Lymphoma
Dosing
Diffuse Large B-Cell Lymphoma 12 mg/kg IV; Cycle 1: Days 1, 4, 8, 15, and 22; Cycles 2-3: Days 1, 8, 15, and 22; Cycle 4 and beyond: Days 1 and 15 of each 28-day cycle; in combination with lenalidomide for up to 12 cycles, then MONJUVI as monotherapy until disease progression or unacceptable toxicity.
Diffuse Large B-Cell Lymphoma 0.15 mg/kg IV over 30 minutes every 3 weeks for 2 cycles, then 0.075 mg/kg every 3 weeks for subsequent cycles; premedicate with dexamethasone 4 mg orally or IV twice daily for 3 days beginning the day before administration.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Neutropenia, fatigue, anemia, diarrhea, thrombocytopenia, cough, pyrexia, peripheral edema, respiratory tract infection, decreased appetite
Serious Infections (including pneumonia, febrile neutropenia), cerebrovascular accident, respiratory failure, progressive multifocal leukoencephalopathy, sudden death
Most common (>20%) Thrombocytopenia, increased GGT, neutropenia, anemia, hyperglycemia, transaminase elevation, fatigue, hypoalbuminemia, rash, edema, nausea, musculoskeletal pain.
Serious Febrile neutropenia, pneumonia, edema, pleural effusion, sepsis.
Postmarketing Telangiectasia, cutaneous collagenous vasculopathy, blister, rash vesicular.
Pharmacology
Tafasitamab-cxix is an Fc-modified CD19-directed monoclonal antibody that mediates B-cell lysis through apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP); in combination with lenalidomide, it demonstrates increased ADCC activity in DLBCL tumor cells.
Loncastuximab tesirine-lpyl is a CD19-directed antibody-drug conjugate (ADC); upon binding to CD19, the conjugate is internalized and releases SG3199, a PBD dimer alkylating agent that forms cytotoxic DNA interstrand crosslinks, inducing cell death in B-lineage cells.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Monjuvi
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
Zynlonta
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Monjuvi
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zynlonta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Monjuvi
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Zynlonta
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableCancerCare: Non-Hodgkin Lymphoma
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableADVANCING Patient Support Patient Assistance Program: Zynlonta
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
MonjuviView full Monjuvi profile
ZynlontaView full Zynlonta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.